Company: RVRC
Filing Date: 2025-08-13
Form Type: S-1/A
Source: 0001213900-25-075747
Chunk: 82

Company: Revium Rx.
Filing Date: 2025-08-13
Form: S-1/A
Chunk 82
---
 infection model, female
CD-1 (ICR) mice (5–6 weeks old) were rendered neutropenic via cyclophosphamide (150 mg/kg and 100 mg/kg on days -4 and -1). Mice
were anesthetized and intranasally inoculated with ~5 × 10⁷ CFU of MRSA (UNT141-3). Treatment groups (n=5 per group) received
IV doses of Nano-Mupirocin (50 or 75 mg/kg), free mupirocin (same doses), or blank liposomes 2 hours post-inoculation. Additional control
groups were treated with vancomycin. Mice were euthanized at 24 hours, and lung bacterial loads were measured by plating organ homogenates
on selective agar. Nano-Mupirocin-treated groups showed up to 2.28 log₁₀ CFU reductions compared to free mupirocin at equivalent
doses.

<div align='center'>49</div>

Below are representative figures from the Neutropenic Lung Infection
animal model experiment

| Fig. 2. Therapeutic                                                                                                                             
 effect of parenterally administered Nano-mupirocin or free mupirocin against MRSA in a neutropenic murine model of lung infection. (A)          
 Schematic illustration of therapeutic regimen in neutropenic mice. CD1 mice were rendered neutropenic and infected intranasally with            
 app. 5×107 CFU of MRSA strain UNT141-3 and treated with the indicated dose of either Nanomupirocin, free mupirocin, vancomycin                  
 or with blank nanoliposomes. Mice were sacrificed at 24 h of infection and bacteria enumerated in the lungs. (B) Bacterial loads in the         
 lungs of the different groups of mice treated according to scheme depicted in (A) at 24 h of infection. Each symbol represents the value        
 for an individual animal (n=5). Horizontal lines indicate the mean ± SD.                                                                        
 Reference: Liposomal mupirocin holds promise for systemic treatment of invasive Staphylococcus aureus infections; Oliver Goldmanna,,            
 Ahuva Cernb, Mathias Mueskenc, Manfred Rohdec, William Weissd, Yechezkel Barenholzb,, Eva Medinaa https://doi.org/10.1016/j.jconrel.2019.11.007 |

|